<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02080455</url>
  </required_header>
  <id_info>
    <org_study_id>AEGR-733-024</org_study_id>
    <nct_id>NCT02080455</nct_id>
  </id_info>
  <brief_title>Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Lomitapide in Healthy Subjects.</brief_title>
  <official_title>A Phase 1, Open-Label, Randomized, 2-Arm Study to Evaluate the Effect of Atorvastatin, a Weak CYP3A4 Inhibitor, on the Pharmacokinetics of Lomitapide in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aegerion Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aegerion Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the effect of atorvastatin, a weak
      cytochrome P450 (CYP) 3A4 inhibitor, on the pharmacokinetics (PK) of lomitapide and its 2
      primary metabolites, M1 and M3.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a single center, randomized, open-label, 2-arm study to evaluate the
      effects of atorvastatin, a weak CYP3A4 inhibitor, on the PK of lomitapide in healthy male and
      female subjects when atorvastatin is administered simultaneously with lomitapide and when it
      is administered 12 hours after lomitapide.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 27, 2014</start_date>
  <completion_date type="Actual">March 7, 2014</completion_date>
  <primary_completion_date type="Actual">March 7, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing</time_frame>
    <description>Maximum observed plasma concentration of lomitapide and its 2 primary metabolites (M1 &amp; M3), following administration of lomitapide alone and coadministered with atorvastatin simultaneously (Arm 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing</time_frame>
    <description>Time to reach maximum observed plasma concentration of lomitapide and its 2 primary metabolites (M1 &amp; M3), following administration of lomitapide alone and coadministered with atorvastatin simultaneously (Arm 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing</time_frame>
    <description>Area under the concentration-time curve from zero to the last quantifiable concentration of lomitapide and its 2 primary metabolites (M1 &amp; M3), following administration of lomitapide alone and coadministered with atorvastatin simultaneously (Arm 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing</time_frame>
    <description>Area under the concentration-time curve from zero to infinity of lomitapide and its 2 primary metabolites (M1 &amp; M3), following administration of lomitapide alone and coadministered with atorvastatin simultaneously (Arm 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2</measure>
    <time_frame>Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing</time_frame>
    <description>Apparent terminal elimination half-life of lomitapide and its 2 primary metabolites (M1 &amp; M3), following administration of lomitapide alone and coadministered with atorvastatin simultaneously (Arm 1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing</time_frame>
    <description>Maximum observed plasma concentration of lomitapide and its 2 primary metabolites (M1 &amp; M3) following administration of lomitapide alone and coadministered with atorvastatin 12 hours apart (Arm 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing</time_frame>
    <description>Time to reach maximum observed plasma concentration of lomitapide and its 2 primary metabolites (M1 &amp; M3) following administration of lomitapide alone and coadministered with atorvastatin 12 hours apart (Arm 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing</time_frame>
    <description>Area under the concentration-time curve from zero to the last quantifiable concentration of lomitapide and its 2 primary metabolites (M1 &amp; M3) following administration of lomitapide alone and coadministered with atorvastatin 12 hours apart (Arm 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing</time_frame>
    <description>Area under the concentration-time curve from zero to infinity of lomitapide and its 2 primary metabolites (M1 &amp; M3) following administration of lomitapide alone and coadministered with atorvastatin 12 hours apart (Arm 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing</time_frame>
    <description>Apparent terminal elimination half-life of lomitapide and its 2 primary metabolites (M1 &amp; M3) following administration of lomitapide alone and coadministered with atorvastatin 12 hours apart (Arm 2)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Effect of Atorvastatin on the Pharmacokinetics of Lomitapide</condition>
  <arm_group>
    <arm_group_label>Lomitapide &amp; Atorvastatin - Taken Together</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 single oral doses of lomitapide (20 mg) with a 14-day washout between (Day 1 &amp; Day 15)
11 single oral doses of atorvastatin (80 mg) (Day 11 through day 21)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lomitapide &amp; Atorvastatin - Approx. 12 hours between</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 single oral doses of lomitapide (20 mg) with a 14-day washout between (Day 1 &amp; Day 15)
11 single oral doses of atorvastatin (80 mg) (Day 12 through day 22)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lomitapide</intervention_name>
    <description>20 mg dose</description>
    <arm_group_label>Lomitapide &amp; Atorvastatin - Approx. 12 hours between</arm_group_label>
    <arm_group_label>Lomitapide &amp; Atorvastatin - Taken Together</arm_group_label>
    <other_name>Juxtapid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>80 mg</description>
    <arm_group_label>Lomitapide &amp; Atorvastatin - Approx. 12 hours between</arm_group_label>
    <arm_group_label>Lomitapide &amp; Atorvastatin - Taken Together</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males and females, between 18 and 55 years of age inclusive

          2. BMI between 18.5 and 32.0 kg/m2, inclusive; total body weight of &gt;110 lbs (50 kg);

          3. in good health, determined by no clinically significant or relevant abnormalities
             identified by a detailed medical history and medical exam

          4. creatine phosphokinase, AST, and ALT levels must be below 1.5 times the upper limit of
             normal

          5. clinical laboratory evaluations within the reference range for the test laboratory

          6. negative test for selected drugs of abuse

          7. negative hepatitis panel and negative HIV antibody screens

          8. males will either be sterile or agree to use approved methods of contraception

          9. all females must have a negative serum beta human chorionic gonadotropin pregnancy
             test and will be required to use a medically acceptable method of contraception.

         10. able to comprehend and willing to sign an Informed Consent Form

        Exclusion Criteria:

          1. significant history or clinical manifestation of any metabolic, allergic,
             dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, GI,
             neurological, or psychiatric disorder

          2. history of significant hypersensitivity, intolerance, or allergy to any drug compound,
             food, or other substance

          3. history of stomach or intestinal surgery or resection

          4. history of Gilbert's Syndrome or suspicion of Gilbert's Syndrome

          5. subjects who have an abnormality in the 12-lead ECG

          6. use of any drugs of abuse for 6 months prior to Check-in;

          7. subjects who consume more than 14 units of alcohol per week or who have a significant
             history of alcoholism or drug/chemical abuse within 1 year prior to Check-in

          8. use of any tobacco- or nicotine-containing products within 6 months prior to Check-in;

          9. participation in any other investigational study drug trial within 30 days prior to
             Check-in;

         10. use of any prescription medications/products within 14 days prior to Check-in unless
             deemed acceptable by the Investigator and Sponsor

         11. use of any over-the-counter, nonprescription preparations within 7 days prior to
             Check-in, unless deemed acceptable by the Investigator and Sponsor

         12. use of alcohol-, grapefruit- (including star fruit), or caffeine-containing foods or
             beverages within 72 hours prior to Check-in and through Study Completion

         13. poor peripheral venous access;

         14. donation of blood (500 mL) from 30 days prior to Screening through Study Completion

         15. receipt of blood products within 2 months prior to Check-in;

         16. any acute or chronic condition, scheduled hospitalization (inclusive of elective
             surgery during study) or scheduled travel prior to completion of all study procedures
             which, in the opinion of the Investigator, would limit the subject's ability to
             complete and/or participate in this clinical study;

         17. subjects who, in the opinion of the Investigator, should not participate in this
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Sumeray, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cheif Medical Officer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>T. Alex King, MD, CPI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit, Inc</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 5, 2014</study_first_submitted>
  <study_first_submitted_qc>March 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2014</study_first_posted>
  <results_first_submitted>June 23, 2015</results_first_submitted>
  <results_first_submitted_qc>February 25, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 10, 2020</results_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lomitapide &amp; Atorvastatin - Taken Together</title>
          <description>2 single oral doses of lomitapide (20 mg) with a 14-day washout between (Day 1 &amp; Day 15)
11 single oral doses of atorvastatin (80 mg) (Day 11 through day 21)
lomitapide: 20 mg dose
Atorvastatin: 80 mg</description>
        </group>
        <group group_id="P2">
          <title>Lomitapide &amp; Atorvastatin - Approx. 12 Hours Between</title>
          <description>2 single oral doses of lomitapide (20 mg) with a 14-day washout between (Day 1 &amp; Day 15)
11 single oral doses of atorvastatin (80 mg) (Day 12 through day 22)
lomitapide: 20 mg dose
Atorvastatin: 80 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lomitapide &amp; Atorvastatin - Taken Together</title>
          <description>2 single oral doses of lomitapide (20 mg) with a 14-day washout between (Day 1 &amp; Day 15)
11 single oral doses of atorvastatin (80 mg) (Day 11 through day 21)
lomitapide: 20 mg dose
Atorvastatin: 80 mg</description>
        </group>
        <group group_id="B2">
          <title>Lomitapide &amp; Atorvastatin - Approx. 12 Hours Between</title>
          <description>2 single oral doses of lomitapide (20 mg) with a 14-day washout between (Day 1 &amp; Day 15)
11 single oral doses of atorvastatin (80 mg) (Day 12 through day 22)
lomitapide: 20 mg dose
Atorvastatin: 80 mg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" spread="9.1"/>
                    <measurement group_id="B2" value="39" spread="9.5"/>
                    <measurement group_id="B3" value="40" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax</title>
        <description>Maximum observed plasma concentration of lomitapide and its 2 primary metabolites (M1 &amp; M3), following administration of lomitapide alone and coadministered with atorvastatin simultaneously (Arm 1)</description>
        <time_frame>Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing</time_frame>
        <population>The PK Population consisted of all subjects who received at least one dose of study drug and have evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>PK of Lomitapide (Lomitapide Alone)</title>
            <description>PK of lomitapide following administration of lomitapide alone</description>
          </group>
          <group group_id="O2">
            <title>PK of Lomitapide (Coadministered Simultaneously)</title>
            <description>PK of lomitapide following administration of lomitapide coadministered with atorvastatin simultaneously</description>
          </group>
          <group group_id="O3">
            <title>PK of M1 (Lomitapide Alone)</title>
            <description>PK of M1 following administration of lomitapide alone</description>
          </group>
          <group group_id="O4">
            <title>PK of M1 (Coadministered Simultaneously)</title>
            <description>PK of M1 following administration of lomitapide coadministered with atorvastatin simultaneously</description>
          </group>
          <group group_id="O5">
            <title>PK of M3 (Lomitapide Alone)</title>
            <description>PK of M3 following administration of lomitapide alone</description>
          </group>
          <group group_id="O6">
            <title>PK of M3 (Coadministered Simultaneously)</title>
            <description>PK of M3 following administration of lomitapide coadministered with atorvastatin simultaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Maximum observed plasma concentration of lomitapide and its 2 primary metabolites (M1 &amp; M3), following administration of lomitapide alone and coadministered with atorvastatin simultaneously (Arm 1)</description>
          <population>The PK Population consisted of all subjects who received at least one dose of study drug and have evaluable PK data.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.940" spread="34.5"/>
                    <measurement group_id="O2" value="2.00" spread="52.9"/>
                    <measurement group_id="O3" value="2.24" spread="22.8"/>
                    <measurement group_id="O4" value="2.11" spread="31.9"/>
                    <measurement group_id="O5" value="32.3" spread="40.6"/>
                    <measurement group_id="O6" value="27.2" spread="62.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax</title>
        <description>Time to reach maximum observed plasma concentration of lomitapide and its 2 primary metabolites (M1 &amp; M3), following administration of lomitapide alone and coadministered with atorvastatin simultaneously (Arm 1)</description>
        <time_frame>Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing</time_frame>
        <population>The PK Population consisted of all subjects who received at least one dose of study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>PK of Lomitapide (Lomitapide Alone)</title>
            <description>PK of lomitapide following administration of lomitapide alone</description>
          </group>
          <group group_id="O2">
            <title>PK of Lomitapide (Coadministered Simultaneously)</title>
            <description>PK of lomitapide following administration of lomitapide coadministered with atorvastatin simultaneously</description>
          </group>
          <group group_id="O3">
            <title>PK of M1 (Lomitapide Alone)</title>
            <description>PK of M1 following administration of lomitapide alone</description>
          </group>
          <group group_id="O4">
            <title>PK of M1 (Coadministered Simultaneously)</title>
            <description>PK of M1 following administration of lomitapide coadministered with atorvastatin simultaneously</description>
          </group>
          <group group_id="O5">
            <title>PK of M3 (Lomitapide Alone)</title>
            <description>PK of M3 following administration of lomitapide alone</description>
          </group>
          <group group_id="O6">
            <title>PK of M3 (Coadministered Simultaneously)</title>
            <description>PK of M3 following administration of lomitapide coadministered with atorvastatin simultaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax</title>
          <description>Time to reach maximum observed plasma concentration of lomitapide and its 2 primary metabolites (M1 &amp; M3), following administration of lomitapide alone and coadministered with atorvastatin simultaneously (Arm 1)</description>
          <population>The PK Population consisted of all subjects who received at least one dose of study drug and had evaluable PK data.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.00" lower_limit="3.00" upper_limit="10.0"/>
                    <measurement group_id="O2" value="10.0" lower_limit="3.00" upper_limit="23.8"/>
                    <measurement group_id="O3" value="6.02" lower_limit="4.00" upper_limit="10.0"/>
                    <measurement group_id="O4" value="10.0" lower_limit="4.00" upper_limit="23.8"/>
                    <measurement group_id="O5" value="4.00" lower_limit="3.00" upper_limit="12.0"/>
                    <measurement group_id="O6" value="6.00" lower_limit="3.00" upper_limit="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t</title>
        <description>Area under the concentration-time curve from zero to the last quantifiable concentration of lomitapide and its 2 primary metabolites (M1 &amp; M3), following administration of lomitapide alone and coadministered with atorvastatin simultaneously (Arm 1)</description>
        <time_frame>Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing</time_frame>
        <population>The PK Population consisted of all subjects who received at least one dose of study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>PK of Lomitapide (Lomitapide Alone)</title>
            <description>PK of lomitapide following administration of lomitapide alone</description>
          </group>
          <group group_id="O2">
            <title>PK of Lomitapide (Coadministered Simultaneously)</title>
            <description>PK of lomitapide following administration of lomitapide coadministered with atorvastatin simultaneously</description>
          </group>
          <group group_id="O3">
            <title>PK of M1 (Lomitapide Alone)</title>
            <description>PK of M1 following administration of lomitapide alone</description>
          </group>
          <group group_id="O4">
            <title>PK of M1 (Coadministered Simultaneously)</title>
            <description>PK of M1 following administration of lomitapide coadministered with atorvastatin simultaneously</description>
          </group>
          <group group_id="O5">
            <title>PK of M3 (Lomitapide Alone)</title>
            <description>PK of M3 following administration of lomitapide alone</description>
          </group>
          <group group_id="O6">
            <title>PK of M3 (Coadministered Simultaneously)</title>
            <description>PK of M3 following administration of lomitapide coadministered with atorvastatin simultaneously</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t</title>
          <description>Area under the concentration-time curve from zero to the last quantifiable concentration of lomitapide and its 2 primary metabolites (M1 &amp; M3), following administration of lomitapide alone and coadministered with atorvastatin simultaneously (Arm 1)</description>
          <population>The PK Population consisted of all subjects who received at least one dose of study drug and had evaluable PK data.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" spread="38.4"/>
                    <measurement group_id="O2" value="71.5" spread="45.3"/>
                    <measurement group_id="O3" value="76.8" spread="34.4"/>
                    <measurement group_id="O4" value="76.3" spread="36.0"/>
                    <measurement group_id="O5" value="434" spread="65.5"/>
                    <measurement group_id="O6" value="475" spread="55.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax</title>
        <description>Maximum observed plasma concentration of lomitapide and its 2 primary metabolites (M1 &amp; M3) following administration of lomitapide alone and coadministered with atorvastatin 12 hours apart (Arm 2)</description>
        <time_frame>Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing</time_frame>
        <population>The PK Population consisted of all subjects who received at least one dose of study drug and have evaluable PK data. 1 subject was removed from formal statistical analysis due to all BLQ values on Day 1 for lomitapide, M1 and M3.</population>
        <group_list>
          <group group_id="O1">
            <title>PK of Lomitapide (Lomitapide Alone)</title>
            <description>PK of lomitapide following administration of lomitapide alone</description>
          </group>
          <group group_id="O2">
            <title>PK of Lomitapide (Coadministered 12 Hours Apart)</title>
            <description>PK of lomitapide following administration of lomitapide coadministered with atorvastatin 12 hours apart</description>
          </group>
          <group group_id="O3">
            <title>PK of M1 (Lomitapide Alone)</title>
            <description>PK of M1 following administration of lomitapide alone</description>
          </group>
          <group group_id="O4">
            <title>PK of M1 (Coadministered 12 Hours Apart)</title>
            <description>PK of M1 following administration of lomitapide coadministered with atorvastatin 12 hours apart</description>
          </group>
          <group group_id="O5">
            <title>PK of M3 (Lomitapide Alone)</title>
            <description>PK of M3 following administration of lomitapide alone</description>
          </group>
          <group group_id="O6">
            <title>PK of M3 (Coadministered 12 Hours Apart)</title>
            <description>PK of M3 following administration of lomitapide coadministered with atorvastatin 12 hours apart</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Maximum observed plasma concentration of lomitapide and its 2 primary metabolites (M1 &amp; M3) following administration of lomitapide alone and coadministered with atorvastatin 12 hours apart (Arm 2)</description>
          <population>The PK Population consisted of all subjects who received at least one dose of study drug and have evaluable PK data. 1 subject was removed from formal statistical analysis due to all BLQ values on Day 1 for lomitapide, M1 and M3.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" spread="49.8"/>
                    <measurement group_id="O2" value="1.39" spread="40.0"/>
                    <measurement group_id="O3" value="2.38" spread="25.5"/>
                    <measurement group_id="O4" value="2.66" spread="25.4"/>
                    <measurement group_id="O5" value="28.5" spread="29.9"/>
                    <measurement group_id="O6" value="35.9" spread="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-∞</title>
        <description>Area under the concentration-time curve from zero to infinity of lomitapide and its 2 primary metabolites (M1 &amp; M3), following administration of lomitapide alone and coadministered with atorvastatin simultaneously (Arm 1)</description>
        <time_frame>Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing</time_frame>
        <population>The PK Population consisted of all subjects who received at least one dose of study drug and had evaluable PK data. 2 subjects were removed from formal statistical analysis of &quot;PK of M3 (Lomitapide alone)&quot; due to missing value of AUC0-∞ for Analyte M3.</population>
        <group_list>
          <group group_id="O1">
            <title>PK of Lomitapide (Lomitapide Alone)</title>
            <description>PK of lomitapide following administration of lomitapide alone</description>
          </group>
          <group group_id="O2">
            <title>PK of Lomitapide (Coadministered Simultaneously)</title>
            <description>PK of lomitapide following administration of lomitapide coadministered with atorvastatin simultaneously</description>
          </group>
          <group group_id="O3">
            <title>PK of M1 (Lomitapide Alone)</title>
            <description>PK of M1 following administration of lomitapide alone</description>
          </group>
          <group group_id="O4">
            <title>PK of M1 (Coadministered Simultaneously)</title>
            <description>PK of M1 following administration of lomitapide coadministered with atorvastatin simultaneously</description>
          </group>
          <group group_id="O5">
            <title>PK of M3 (Lomitapide Alone)</title>
            <description>PK of M3 following administration of lomitapide alone</description>
          </group>
          <group group_id="O6">
            <title>PK of M3 (Coadministered Simultaneously)</title>
            <description>PK of M3 following administration of lomitapide coadministered with atorvastatin simultaneously</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞</title>
          <description>Area under the concentration-time curve from zero to infinity of lomitapide and its 2 primary metabolites (M1 &amp; M3), following administration of lomitapide alone and coadministered with atorvastatin simultaneously (Arm 1)</description>
          <population>The PK Population consisted of all subjects who received at least one dose of study drug and had evaluable PK data. 2 subjects were removed from formal statistical analysis of &quot;PK of M3 (Lomitapide alone)&quot; due to missing value of AUC0-∞ for Analyte M3.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.4" spread="40.8"/>
                    <measurement group_id="O2" value="76.7" spread="45.1"/>
                    <measurement group_id="O3" value="79.1" spread="34.7"/>
                    <measurement group_id="O4" value="78.7" spread="36.3"/>
                    <measurement group_id="O5" value="469" spread="68.6"/>
                    <measurement group_id="O6" value="487" spread="544"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t1/2</title>
        <description>Apparent terminal elimination half-life of lomitapide and its 2 primary metabolites (M1 &amp; M3), following administration of lomitapide alone and coadministered with atorvastatin simultaneously (Arm 1)</description>
        <time_frame>Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing</time_frame>
        <population>The PK Population consisted of all subjects who received at least one dose of study drug and have evaluable PK data. 2 subjects were removed from formal statistical analysis of &quot;PK of M3 (Lomitapide alone)&quot; due to missing value of AUC0-∞ for Analyte M3.</population>
        <group_list>
          <group group_id="O1">
            <title>PK of Lomitapide (Lomitapide Alone)</title>
            <description>PK of lomitapide following administration of lomitapide alone</description>
          </group>
          <group group_id="O2">
            <title>PK of Lomitapide (Coadministered Simultaneously)</title>
            <description>PK of lomitapide following administration of lomitapide coadministered with atorvastatin simultaneously</description>
          </group>
          <group group_id="O3">
            <title>PK of M1 (Lomitapide Alone)</title>
            <description>PK of M1 following administration of lomitapide alone</description>
          </group>
          <group group_id="O4">
            <title>PK of M1 (Coadministered Simultaneously)</title>
            <description>PK of M1 following administration of lomitapide coadministered with atorvastatin simultaneously</description>
          </group>
          <group group_id="O5">
            <title>PK of M3 (Lomitapide Alone)</title>
            <description>PK of M3 following administration of lomitapide alone</description>
          </group>
          <group group_id="O6">
            <title>PK of M3 (Coadministered Simultaneously)</title>
            <description>PK of M3 following administration of lomitapide coadministered with atorvastatin simultaneously</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2</title>
          <description>Apparent terminal elimination half-life of lomitapide and its 2 primary metabolites (M1 &amp; M3), following administration of lomitapide alone and coadministered with atorvastatin simultaneously (Arm 1)</description>
          <population>The PK Population consisted of all subjects who received at least one dose of study drug and have evaluable PK data. 2 subjects were removed from formal statistical analysis of &quot;PK of M3 (Lomitapide alone)&quot; due to missing value of AUC0-∞ for Analyte M3.</population>
          <units>hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.7" spread="22.1"/>
                    <measurement group_id="O2" value="50.4" spread="21.8"/>
                    <measurement group_id="O3" value="34.0" spread="17.7"/>
                    <measurement group_id="O4" value="35.2" spread="16.2"/>
                    <measurement group_id="O5" value="50.2" spread="25.6"/>
                    <measurement group_id="O6" value="43.2" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax</title>
        <description>Time to reach maximum observed plasma concentration of lomitapide and its 2 primary metabolites (M1 &amp; M3) following administration of lomitapide alone and coadministered with atorvastatin 12 hours apart (Arm 2)</description>
        <time_frame>Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing</time_frame>
        <population>The PK Population consisted of all subjects who received at least one dose of study drug and have evaluable PK data. 1 subject was removed from formal statistical analysis due to all BLQ values on Day 1 for lomitapide, M1 and M3.</population>
        <group_list>
          <group group_id="O1">
            <title>PK of Lomitapide (Lomitapide Alone)</title>
            <description>PK of lomitapide following administration of lomitapide alone</description>
          </group>
          <group group_id="O2">
            <title>PK of Lomitapide (Coadministered 12 Hours Apart)</title>
            <description>PK of lomitapide following administration of lomitapide coadministered with atorvastatin 12 hours apart</description>
          </group>
          <group group_id="O3">
            <title>PK of M1 (Lomitapide Alone)</title>
            <description>PK of M1 following administration of lomitapide alone</description>
          </group>
          <group group_id="O4">
            <title>PK of M1 (Coadministered 12 Hours Apart)</title>
            <description>PK of M1 following administration of lomitapide coadministered with atorvastatin 12 hours apart</description>
          </group>
          <group group_id="O5">
            <title>PK of M3 (Lomitapide Alone)</title>
            <description>PK of M3 following administration of lomitapide alone</description>
          </group>
          <group group_id="O6">
            <title>PK of M3 (Coadministered 12 Hours Apart)</title>
            <description>PK of M3 following administration of lomitapide coadministered with atorvastatin 12 hours apart</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax</title>
          <description>Time to reach maximum observed plasma concentration of lomitapide and its 2 primary metabolites (M1 &amp; M3) following administration of lomitapide alone and coadministered with atorvastatin 12 hours apart (Arm 2)</description>
          <population>The PK Population consisted of all subjects who received at least one dose of study drug and have evaluable PK data. 1 subject was removed from formal statistical analysis due to all BLQ values on Day 1 for lomitapide, M1 and M3.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.02" lower_limit="4.00" upper_limit="12.0"/>
                    <measurement group_id="O2" value="8.00" lower_limit="5.00" upper_limit="11.8"/>
                    <measurement group_id="O3" value="8.00" lower_limit="4.00" upper_limit="12.0"/>
                    <measurement group_id="O4" value="8.00" lower_limit="5.07" upper_limit="11.8"/>
                    <measurement group_id="O5" value="6.00" lower_limit="3.00" upper_limit="10.0"/>
                    <measurement group_id="O6" value="5.00" lower_limit="3.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-t</title>
        <description>Area under the concentration-time curve from zero to the last quantifiable concentration of lomitapide and its 2 primary metabolites (M1 &amp; M3) following administration of lomitapide alone and coadministered with atorvastatin 12 hours apart (Arm 2)</description>
        <time_frame>Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing</time_frame>
        <population>The PK Population consisted of all subjects who received at least one dose of study drug and have evaluable PK data. 1 subject was removed from formal statistical analysis due to all BLQ values on Day 1 for lomitapide, M1 and M3.</population>
        <group_list>
          <group group_id="O1">
            <title>PK of Lomitapide (Lomitapide Alone)</title>
            <description>PK of lomitapide following administration of lomitapide alone</description>
          </group>
          <group group_id="O2">
            <title>PK of Lomitapide (Coadministered 12 Hours Apart)</title>
            <description>PK of lomitapide following administration of lomitapide coadministered with atorvastatin 12 hours apart</description>
          </group>
          <group group_id="O3">
            <title>PK of M1 (Lomitapide Alone)</title>
            <description>PK of M1 following administration of lomitapide alone</description>
          </group>
          <group group_id="O4">
            <title>PK of M1 (Coadministered 12 Hours Apart)</title>
            <description>PK of M1 following administration of lomitapide coadministered with atorvastatin 12 hours apart</description>
          </group>
          <group group_id="O5">
            <title>PK of M3 (Lomitapide Alone)</title>
            <description>PK of M3 following administration of lomitapide alone</description>
          </group>
          <group group_id="O6">
            <title>PK of M3 (Coadministered 12 Hours Apart)</title>
            <description>PK of M3 following administration of lomitapide coadministered with atorvastatin 12 hours apart</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t</title>
          <description>Area under the concentration-time curve from zero to the last quantifiable concentration of lomitapide and its 2 primary metabolites (M1 &amp; M3) following administration of lomitapide alone and coadministered with atorvastatin 12 hours apart (Arm 2)</description>
          <population>The PK Population consisted of all subjects who received at least one dose of study drug and have evaluable PK data. 1 subject was removed from formal statistical analysis due to all BLQ values on Day 1 for lomitapide, M1 and M3.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.8" spread="40.8"/>
                    <measurement group_id="O2" value="50.5" spread="26.0"/>
                    <measurement group_id="O3" value="68.3" spread="33.0"/>
                    <measurement group_id="O4" value="77.6" spread="27.9"/>
                    <measurement group_id="O5" value="410" spread="32.6"/>
                    <measurement group_id="O6" value="542" spread="31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-∞</title>
        <description>Area under the concentration-time curve from zero to infinity of lomitapide and its 2 primary metabolites (M1 &amp; M3) following administration of lomitapide alone and coadministered with atorvastatin 12 hours apart (Arm 2)</description>
        <time_frame>Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing</time_frame>
        <population>The PK Population consisted of all subjects who received at least one dose of study drug and have evaluable PK data. 3 subjects were removed from formal statistical analysis due to BLQ values on Day 1, missing value of AUC0-∞ on Day 1, and missing value of AUC0-∞ on Day 15.</population>
        <group_list>
          <group group_id="O1">
            <title>PK of Lomitapide (Lomitapide Alone)</title>
            <description>PK of lomitapide following administration of lomitapide alone</description>
          </group>
          <group group_id="O2">
            <title>PK of Lomitapide (Coadminister 12 Hours Apart)</title>
            <description>PK of lomitapide following administration of lomitapide coadministered with atorvastatin 12 hours apart</description>
          </group>
          <group group_id="O3">
            <title>PK of M1 (Lomitapide Alone)</title>
            <description>PK of M1 following administration of lomitapide alone</description>
          </group>
          <group group_id="O4">
            <title>PK of M1 (Coadministered 12 Hours Apart)</title>
            <description>PK of M1 following administration of lomitapide coadministered with atorvastatin 12 hours apart</description>
          </group>
          <group group_id="O5">
            <title>PK of M3 (Lomitapide Alone)</title>
            <description>PK of M3 following administration of lomitapide alone</description>
          </group>
          <group group_id="O6">
            <title>PK of M3 (Coadministered 12 Hours Apart)</title>
            <description>PK of M3 following administration of lomitapide coadministered with atorvastatin 12 hours apart</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞</title>
          <description>Area under the concentration-time curve from zero to infinity of lomitapide and its 2 primary metabolites (M1 &amp; M3) following administration of lomitapide alone and coadministered with atorvastatin 12 hours apart (Arm 2)</description>
          <population>The PK Population consisted of all subjects who received at least one dose of study drug and have evaluable PK data. 3 subjects were removed from formal statistical analysis due to BLQ values on Day 1, missing value of AUC0-∞ on Day 1, and missing value of AUC0-∞ on Day 15.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.8" spread="39.6"/>
                    <measurement group_id="O2" value="55.8" spread="25.2"/>
                    <measurement group_id="O3" value="70.0" spread="32.8"/>
                    <measurement group_id="O4" value="79.2" spread="27.8"/>
                    <measurement group_id="O5" value="406" spread="30.8"/>
                    <measurement group_id="O6" value="553" spread="32.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t1/2</title>
        <description>Apparent terminal elimination half-life of lomitapide and its 2 primary metabolites (M1 &amp; M3) following administration of lomitapide alone and coadministered with atorvastatin 12 hours apart (Arm 2)</description>
        <time_frame>Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing</time_frame>
        <population>The PK Population consisted of all subjects who received at least one dose of study drug and have evaluable PK data. 3 subjects were removed from formal statistical analysis due to BLQ values on Day 1, missing value of AUC0-∞ on Day 1, and missing value of AUC0-∞ on Day 15.</population>
        <group_list>
          <group group_id="O1">
            <title>PK of Lomitapide (Lomitapide Alone)</title>
            <description>PK of lomitapide following administration of lomitapide alone</description>
          </group>
          <group group_id="O2">
            <title>PK of Lomitapide (Coadministered 12 Hours Apart)</title>
            <description>PK of lomitapide following administration of lomitapide coadministered with atorvastatin 12 hours apart</description>
          </group>
          <group group_id="O3">
            <title>PK of M1 (Lomitapide Alone)</title>
            <description>PK of M1 following administration of lomitapide alone</description>
          </group>
          <group group_id="O4">
            <title>PK of M1 (Coadministered 12 Hours Apart)</title>
            <description>PK of M1 following administration of lomitapide coadministered with atorvastatin 12 hours apart</description>
          </group>
          <group group_id="O5">
            <title>PK of M3 (Lomitapide Alone)</title>
            <description>PK of M3 following administration of lomitapide alone</description>
          </group>
          <group group_id="O6">
            <title>PK of M3 (Coadministered 12 Hours Apart)</title>
            <description>PK of M3 following administration of lomitapide coadministered with atorvastatin 12 hours apart</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2</title>
          <description>Apparent terminal elimination half-life of lomitapide and its 2 primary metabolites (M1 &amp; M3) following administration of lomitapide alone and coadministered with atorvastatin 12 hours apart (Arm 2)</description>
          <population>The PK Population consisted of all subjects who received at least one dose of study drug and have evaluable PK data. 3 subjects were removed from formal statistical analysis due to BLQ values on Day 1, missing value of AUC0-∞ on Day 1, and missing value of AUC0-∞ on Day 15.</population>
          <units>hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.0" spread="19.5"/>
                    <measurement group_id="O2" value="54.7" spread="28.5"/>
                    <measurement group_id="O3" value="31.2" spread="24.0"/>
                    <measurement group_id="O4" value="32.3" spread="18.2"/>
                    <measurement group_id="O5" value="48.0" spread="33.4"/>
                    <measurement group_id="O6" value="49.7" spread="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lomitapide &amp; Atorvastatin - Taken Together</title>
          <description>2 single oral doses of lomitapide (20 mg) with a 14-day washout between (Day 1 &amp; Day 15)
11 single oral doses of atorvastatin (80 mg) (Day 11 through day 21)
lomitapide: 20 mg dose
Atorvastatin: 80 mg</description>
        </group>
        <group group_id="E2">
          <title>Lomitapide &amp; Atorvastatin - Approx. 12 Hours Between</title>
          <description>2 single oral doses of lomitapide (20 mg) with a 14-day washout between (Day 1 &amp; Day 15)
11 single oral doses of atorvastatin (80 mg) (Day 12 through day 22)
lomitapide: 20 mg dose
Atorvastatin: 80 mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Lip Dry</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appitite</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Skin Irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Described in site contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alison Long, MD - VP Clinical</name_or_title>
      <organization>Aegerion Pharmaceuticals, Inc.</organization>
      <phone>617-242-5142</phone>
      <email>alison.long@aegerion.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

